Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDAR: Immediate versus delayed azathioprine or rituximab in pediatric MOGAD
2024-516243-81-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azathioprine and rituximab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Annualized relapse rate at 24 months. Planned start Oct 2024; status: authorised.
02
Drugs
azathioprinerituximab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on 2024-516243-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516243-81-00.